ELMIRON CAPSULE

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

PENTOSAN POLYSULFATE SODIUM

Предлага се от:

JANSSEN INC

АТС код:

C05BA04

INN (Международно Name):

PENTOSTAN POLYSULFATE SODIUM

дозиране:

100MG

Лекарствена форма:

CAPSULE

Композиция:

PENTOSAN POLYSULFATE SODIUM 100MG

Начин на приложение:

ORAL

Броя в опаковка:

100

Вид предписание :

Prescription

Терапевтична област:

MISCELLANEOUS THERAPEUTIC AGENTS

Каталог на резюме:

Active ingredient group (AIG) number: 0124416001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2002-05-01

Данни за продукта

_ _
_ _
_Page 1 of 21 _
PRODUCT MONOGRAPH
PR
ELMIRON
®*
pentosan polysulfate sodium
Capsules 100 mg
Glycosaminoglycan Substitute
Janssen Inc.
19 Green Belt Drive
Toronto, Ontario
M3C 1L9
www.janssen.com/canada
Date of Preparation:
September 28, 1998
Date of Revision:
October 1, 2020
Submission Control No: 239842
*Registered trademark of IVAX Research, LLC. Used under license.
©2020 JANSSEN Inc.
_ _
_ _
_Page 2 of 21 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DRUG INTERACTIONS
....................................................................................................8
DOSAGE AND ADMINISTRATION
................................................................................8
OVERDOSAGE
..................................................................................................................8
ACTION AND CLINICAL PHARMACOLOGY
............................................................10
STORAGE AND STABILITY
..........................................................................................11
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................11
PART II: SCIENTIFIC INFORMATION
...............................................................................12
PHARMACEUTICAL INFORMATION
..........................................................................12
CLINICAL TRIALS
...........................................................